Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy

Mol Genet Metab. 2020 Aug;130(4):262-273. doi: 10.1016/j.ymgme.2020.06.007. Epub 2020 Jun 24.

Abstract

Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disease (LSD) caused by a deficiency of the iduronate-2-sulfatase (IDS) that catabolizes glycosaminoglycans (GAGs). Abnormal accumulations of GAGs in somatic cells lead to various manifestations including central nervous system (CNS) disease. Enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) are the currently available therapy for MPS II, but both therapies fail to improve CNS manifestations. We previously showed that hematopoietic stem cell targeted gene therapy (HSC-GT) with lethal irradiation improved CNS involvement in a murine model of MPS II which lacks the gene coding for IDS. However, the strong preconditioning, with lethal irradiation, would cause a high rate of morbidity and mortality. Therefore, we tested milder preconditioning procedures with either low dose irradiation or low dose irradiation plus an anti c-kit monoclonal antibody (ACK2) to assess CNS effects in mice with MPS II after HSC-GT. Mice from all the HSC-GT groups displayed super-physiological levels of IDS enzyme activity and robust reduction of abnormally accumulated GAGs to the wild type mice levels in peripheral organs. However, only the mice treated with lethal irradiation showed significant cognitive function improvement as well as IDS elevation and GAG reduction in the brain. These results suggest that an efficient engraftment of genetically modified cells for HSC-GT requires strong preconditioning to ameliorate CNS involvement in cases with MPS II.

Keywords: Ex vivo; Gene therapy; Hunter syndrome; Lentivirus vector; Mucopolysaccharidosis type II; Preconditioning.

MeSH terms

  • Animals
  • Central Nervous System Diseases / enzymology
  • Central Nervous System Diseases / etiology
  • Central Nervous System Diseases / genetics
  • Central Nervous System Diseases / therapy*
  • Disease Models, Animal
  • Enzyme Replacement Therapy*
  • Female
  • Genetic Therapy*
  • Glycosaminoglycans / analysis
  • Hematopoietic Stem Cell Transplantation / methods*
  • Hematopoietic Stem Cells / cytology*
  • Iduronate Sulfatase / administration & dosage*
  • Iduronate Sulfatase / genetics
  • Mice
  • Mice, Inbred C57BL
  • Mucopolysaccharidosis II / complications*

Substances

  • Glycosaminoglycans
  • Iduronate Sulfatase